Odevixibat
Bylvay (odevixibat) is a prescription medication designed to treat pruritus (itching) in patients with progressive familial intrahepatic cholestasis (PFIC), a rare genetic liver disorder. It works as an ileal bile acid transporter inhibitor, reducing the reabsorption of bile acids in the small intestine. This medication is approved for use in adults and children aged 3 months and older.
Bylvay is a prescription therapy for itching associated with PFIC, a rare genetic liver condition, working by blocking bile acid reabsorption in the intestine.
Key facts at a glance
- RxNorm
- 2563984
- Generic
- Bylvay
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Bylvay is indicated for the treatment of pruritus (itching) in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). PFIC is a rare genetic disorder that causes progressive liver disease and impairs bile flow, leading to bile acid buildup that causes severe itching and liver damage.
Bylvay is an ileal bile acid transporter (IBAT) inhibitor. It acts locally in the small intestine to block the uptake of bile acids from the gut, reducing the amount of bile acids returning to the liver. By interrupting this enterohepatic circulation, it helps lower bile acid levels in the bloodstream, which is believed to be the mechanism that reduces the itching associated with PFIC.
Bylvay is taken once daily with a meal. Common side effects may include diarrhea, stomach pain, and weight gain. Liver function should be monitored during treatment. It is contraindicated in patients with evidence of extrahepatic bile duct obstruction. The capsules may be opened and sprinkled on soft food for patients who have difficulty swallowing. Patients should consult their healthcare provider for complete safety information and appropriate monitoring.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed September 3, 2026. · Read our editorial policy